Applied DNA Enters into Multi-Year Commercialization Agreement with Indus Group for Large-Scale Implementation of CertainT Cotton TraceabilityAccesswire • Thursday
U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation ContractAccesswire • 07/18/24
Applied DNA Sciences (APDN) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 06/27/24
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform EconomicsAccesswire • 06/20/24
Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) TestingAccesswire • 06/18/24
Applied DNA Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of HealthAccesswire • 06/13/24
Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea(TM) IVT PlatformAccesswire • 06/05/24
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AMLAccesswire • 05/13/24
Applied DNA Sciences (APDN) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 05/10/24
Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production StartAccesswire • 03/18/24
Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine CongressAccesswire • 03/14/24
Is Applied DNA Sciences (APDN) Outperforming Other Industrial Products Stocks This Year?Zacks Investment Research • 02/21/24
Applied DNA Sciences (APDN) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 02/08/24
Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024Accesswire • 02/05/24
Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesAccesswire • 02/02/24
Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesAccesswire • 01/31/24